ESMO

LBA8.mp4
Presidential Session
LBA8 – A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial
Session: Presidential 2
Meeting: ESMO Congress 2023
Date: October 22, 2023
LBA9.mp4
Presidential Session
LBA9 – innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Session: Presidential 2
Meeting: ESMO Congress 2023
Date: October 22, 2023
LBA38.mp4
Proffered Paper Session
LBA38 – Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Session: Gynaecological cancers
Meeting: ESMO Congress 2023
Date: October 20, 2023
IO in combination with chemoradiation therapy in locally advanced cervical cance
Educational Session
IO in combination with chemoradiation therapy in locally advanced cervical cancer
Session: Integrating immunotherapy into the standard of care for cervical cancer
Meeting: ESMO Congress 2023
Date: October 21, 2023
In metastatic and recurrence .mp4
Educational Session
In metastatic and recurrence
Session: Integrating immunotherapy into the standard of care for cervical cancer
Meeting: ESMO Congress 2023
Date: October 21, 2023
Treatment after progression on immunotherapy.mp4
Educational Session
Treatment after progression on immunotherapy
Session: Integrating immunotherapy into the standard of care for cervical cancer
Meeting: ESMO Congress 2023
Date: October 21, 2023
Cervial Cancer.mp4
Special Symposium
Cervical cancer
Session: Molecular profiling of gynaecological cancers for therapeutic stratification
Meeting: ESMO Congress 2023
Date: October 22, 2023
Presentation by Expert .mp4
Challenge Your Expert
Presentation by Expert
Session: Tertiary lymphoid structures: The control centre of immune responses against tumors
Meeting: ESMO Congress 2023
Date: October 22, 2023
Ideal duration of IT How to define it and what are the implications .mp4
Special Symposium
Ideal duration of IT: How to define it and what are the implications
Session: Long term survivors in the era of immunotherapy of cancer
Meeting: ESMO Congress 2023
Date: October 23, 2023
Modulating TME to overcome primary and acquired resistance .mp4
Educational Session
Modulating TME to overcome primary and acquired resistance
Session: Therapeutic view on tumour immune microenvironment: It's TIME
Meeting: ESMO Congress 2023
Date: October 20, 2023
Metabolism at the center stage of cancer drug resistance - cover
Oral Session
Metabolism at the center stage of cancer drug resistance
Session: New resistance to cancer therapies
Meeting: Molecular Analysis for Precision Oncology Congress
Date: October 16, 2022
Predictive biomarkers for I-O toxicity
Oral Session
Predictive biomarkers for I-O toxicity
Session: What should be the optimal biomarker analysis plan to design clinical trial?
Meeting: ESMO Immuno-Oncology Congress 2021
Date: December 10, 2021
Analysis of postoperative adjuvant chemotherapy in 102 patients with gastric-type mucinous carcinoma of the uterine cervix: A multi-institutional study
ePoster Display
Analysis of postoperative adjuvant chemotherapy in 102 patients with gastric-type mucinous carcinoma of the uterine cervix: A multi-institutional study
Session: Therapy; Rare Cancers
Meeting: ESMO Congress 2021
Date: September 16, 2021
Circulating biomarkers of response to immunotherapy
Oral Session
Circulating biomarkers of response to immunotherapy
Session: Optimising I-O drug clinical development
Meeting: ESMO Immuno-Oncology Congress 2021
Date: December 8, 2021
Differences in the tumour immune microenvironment of adeno- vs. squamous cell carcinoma of the uterine cervix: Consequences for immunotherapy
Oral Session
Differences in the tumour immune microenvironment of adeno- vs. squamous cell carcinoma of the uterine cervix: Consequences for immunotherapy
Session: Tumour microenvironment
Meeting: ESMO Immuno-Oncology Congress 2021
Date: December 11, 2021
Biomarkers in clinical practice and future perspective for gynaecological cancers
Special Session
Biomarkers in clinical practice and future perspective for gynaecological cancers
Meeting: ESMO Gynaecological Cancers Congress 2022
Date: June 17, 2022
The evolving landscape in cervical cancer treatment
Educational Session
The evolving landscape in cervical cancer treatment
Meeting: ESMO Gynaecological Cancers Congress 2022
Date: June 18, 2022
Longer follow up of a real-world study of cemiplimab in advanced cutaneous squamous cell carcinoma: Focus on late toxicities and long term benefit
Poster Session
Longer follow up of a real-world study of cemiplimab in advanced cutaneous squamous cell carcinoma: Focus on late toxicities and long term benefit
Meeting: ESMO Congress 2022
Date: September 10, 2022
Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial
Proffered Paper Session
Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial
Session: NSCLC, Metastatic
Meeting: ESMO Congress 2022
Date: September 11, 2022
Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358
Mini Oral Session
Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358
Session: Gynaecological Cancers
Meeting: ESMO Congress 2022
Date: September 10, 2022
Survival analysis of patients with locally advanced cervical cancer treated with cisplatin and gemcitabine concomitantly to radiotherapy followed by consolidation chemotherapy
Poster Session
Survival analysis of patients with locally advanced cervical cancer treated with cisplatin and gemcitabine concomitantly to radiotherapy followed by consolidation chemotherapy
Session: Therapy
Meeting: ESMO Congress 2022
Randomized phase III trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial
Proffered Paper Session
Randomized phase III trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial
Session: Gynaecological Cancers
Meeting: ESMO Congress 2022
Date: September 9, 2022
Stage IVB cervical cancer: Does definitive chemoradiation effect oncological outcomes?
Poster Session
Stage IVB cervical cancer: Does definitive chemoradiation effect oncological outcomes?
Session: Radiation Oncology
Meeting: ESMO Congress 2022
Date: September 10, 2022
Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis
Mini Oral Session
Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis
Session: Clinical Research; Immunotherapy
Meeting: ESMO Congress 2022
Date: September 10, 2022
Survival outcomes in cervical cancer: What factors affect recurrence?
ePoster Display
Survival outcomes in cervical cancer: What factors affect recurrence?
Meeting: ESMO Congress 2021
Date: September 16, 2021
Circulating human papillomavirus DNA as a biomarker of response in advanced cervical cancer
ePoster Display
Circulating human papillomavirus DNA as a biomarker of response in advanced cervical cancer
Meeting: ESMO Congress 2021
Date: September 16, 2021
Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study
Mini Oral Session
Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study
Session: Gynaecological Cancers
Meeting: ESMO Congress 2021
Date: September 19, 2021
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
Presidential Symposium
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
Meeting: ESMO Congress 2021
Date: September 18, 2021
Impact of cemiplimab on quality of life (QoL), functioning and symptoms in patients (pts) with recurrent/metastatic (R/M) cervical carcinoma: Results from EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9
ePoster Display
Impact of cemiplimab on quality of life (QoL), functioning and symptoms in patients (pts) with recurrent/metastatic (R/M) cervical carcinoma: Results from EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9
Session: Ana Oaknin
Meeting: ESMO Congress 2021
Date: September 16, 2021
EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
Virtual Plenary Debate
EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
Meeting: ESMO Congress 2021
Date: September 17, 2021
MedEngine is provided by Springer Healthcare. Part of the Springer Nature Group.
Privacy policy
Terms & conditions
Disclaimer

Welcome. To access this content please provide the following information.

This content was selected by and is provided to you courtesy of Sanofi K.K.

Disclaimer | Privacy policy | Terms & conditions